<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905329</url>
  </required_header>
  <id_info>
    <org_study_id>DS_v01</org_study_id>
    <nct_id>NCT04905329</nct_id>
  </id_info>
  <brief_title>A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations</brief_title>
  <acronym>Def_Special</acronym>
  <official_title>Defendor Special: A Multicenter Prospective Observational Post-registration Study of Combined Chemotherapy With Empegfilrastim Support to Evaluate Safety and Efficacy in Patients With High and &quot;Gray Zone&quot; Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moscow Clinical Scientific Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moscow Clinical Scientific Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the efficacy and safety of Extimia® (INN -&#xD;
      empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile&#xD;
      neutropenia and infections caused by febrile neutropenia in patients with High and &quot;Gray&#xD;
      Zone&quot; Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative dose-intensity (RDI) of the myelosupressive therapy course</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RDI of 6 x TC, 6 x TCHP, ddAC x4 -&gt; 4 x paclitaxel , dd4AC -&gt; 4 x paclitaxel + 12 x carboplatin) regimens performed in relation to (neo) adjuvant therapy of breast cancer</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDI of FOLFOX-, FOLFOXIRI-based regimens performed in relation to (neo) adjuvant therapy of colorectal cancer</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDI of FOLFOX-, FOLFOXIRI-based regimens performed in relation to patients with potentially resectable liver metastases of colorectal cancer</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDI of DCF-, FOLFORINOX-based regimens performed in relation to therapy of pancreatic cancer</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDI of DCF-, FOLFORINOX-, FLOT-, FOLFOX-based regimens performed in relation to therapy of gastric and esophageal cancers</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDI of chemotherapy courses performed in patients with cervical cancer and sarcoma of the uterus after irradiation of the pelvic organs</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The complete pathological responses (pCR) rate in the primary tumors for patients diagnosed with HER2 + and triple negative early breast cancer requiring neoadjuvant treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The complete pathological responses (pCR) rate in the malignant lymph nodes for patients diagnosed with HER2 + and triple negative early breast cancer requiring neoadjuvant treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of febrile neutropenia with empegfilgrastim supportive therapy compared with historical control</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of neutropenia leading to a dose reduction of cytostatic drugs and / or an increase of the interval between cycles when using empegfilgrastim supportive therapy compared with historical controls</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completed cases number of (neo) adjuvant therapy</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe infections (grade 3-4)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of antibiotic prescription</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of study withdrawal due to adverse events</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RCB rate in patients with breast cancer</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any grade adverse events frequency</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events frequency</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">285</enrollment>
  <condition>Solid Tumor</condition>
  <condition>High-Risk Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Gynecological Malignancies</condition>
  <condition>Myelosuppression</condition>
  <arm_group>
    <arm_group_label>Patients with high and &quot;gray zone&quot; risk reccurrence early breast cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with gastointestinal cancers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with gynecological malignancies</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empegfilgrastim</intervention_name>
    <description>Extimia®</description>
    <arm_group_label>Patients with gastointestinal cancers</arm_group_label>
    <arm_group_label>Patients with gynecological malignancies</arm_group_label>
    <arm_group_label>Patients with high and &quot;gray zone&quot; risk reccurrence early breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with high and &quot;gray zone&quot; risk reccurrence breast cancer, gastointestinal cancers&#xD;
        and gynecological malignancies who are prescribed myelosuppressive therapy with&#xD;
        empegfilgrastim supportive therapy to support planned RDI, reduce the frequency, duration&#xD;
        of neutropenia, the incidence of febrile neutropenia (FN) and infections manifested by FN,&#xD;
        as part of routine clinical practice according to the approved indications of the&#xD;
        appropriate drugs.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form;&#xD;
&#xD;
          2. Histologically verified diagnosis;&#xD;
&#xD;
          3. Age between 18 and 80 years; If the patient had previously received chemotherapy for&#xD;
             these indications, then it should be completed at least 30 days before the first&#xD;
             administration of the study drug;&#xD;
&#xD;
          4. ECOG performance 0-2;&#xD;
&#xD;
          5. Haematology:&#xD;
&#xD;
               -  ANC ≥ 1,5 х 10(9) /L;&#xD;
&#xD;
               -  Platelets ≥ 100 х 10(9) /L;&#xD;
&#xD;
               -  Hemoglobin ≥ 90 g/L;&#xD;
&#xD;
          6. Biochemistry:&#xD;
&#xD;
               -  Creatinine ≤ 1,5 ULN;&#xD;
&#xD;
               -  Total bilirubin ≤ 1,5 ULN;&#xD;
&#xD;
               -  AST/ALT ≤ 2,5 ULN;&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 5 ULN;&#xD;
&#xD;
        8. Life expectancy of at least 6 months from the date of the first drug administration in&#xD;
        the study; 9. Ability of the patient to comply with the Protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented hypersensitivity to empegfilgrastim, filgrastim, pegfilgrastim, and / or&#xD;
             their constituent excipients: pegylated drugs, protein recombinant drugs;&#xD;
&#xD;
          2. Systemic use of antibiotics less than 72 hours before the first drug administration in&#xD;
             the study;&#xD;
&#xD;
          3. Concurrent or less than 30 days before the start of the study, radiation therapy (with&#xD;
             the exception of point radiation therapy for bone metastases); study;&#xD;
&#xD;
          4. Concurrent participation in clinical trials, participation in clinical trials within&#xD;
             the previous 30 days, previous participation in this study;&#xD;
&#xD;
          5. Surgical treatment less than 21 days (3 weeks) prior to study enrollment; taking any&#xD;
             experimental medications less than 30 days before enrollment in this study;&#xD;
&#xD;
          6. History of bone marrow or hematopoietic stem cell transplantation;&#xD;
&#xD;
          7. Presence of acute or active chronic infections;&#xD;
&#xD;
          8. Other diseases (with the exception of the main one) that could affect the assessment&#xD;
             of the severity of the symptoms of the underlying disease: that may mask, enhance,&#xD;
             change the symptoms of the underlying disease or cause clinical manifestations and&#xD;
             changes in the data of laboratory and instrumental research methods;&#xD;
&#xD;
          9. Inability to administer the drug by intravenous infusion or subcutaneous injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inna Ganshina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lyudmila Zhukova, MD, PhD, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Moscow Clinical Scientific Center named after AS Loginov</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexey Tryakin, MD, PhD, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikhail Fedyanin, MD, PhD, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Svetlana Khokhlova, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FSBI &quot;National medical research center for obstetrics, gynecology and perinatology named after academician VI Kulakov&quot; Ministry of healthcare of the Russian Federation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lyudmila Zhukova, MD, PhD, professor</last_name>
    <phone>+74953043035</phone>
    <email>lyudmila.zhukova@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moscow Clinical Scientific Center named after AS Loginov</name>
      <address>
        <city>Moscow</city>
        <state>Not Required</state>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyudmila Zhukova, MD, PhD, professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia</name>
      <address>
        <city>Moscow</city>
        <state>Not Required</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Tryakin, MD, PhD, professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Inna Ganshina, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mikhail Fedyanin, MD, PhD, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inna Ganshina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexey Tryakin, MD, PhD, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;National medical research center for obstetrics, gynecology and perinatology named after academician VI Kulakov&quot; Ministry of healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Svetlana Khlokhlova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Svetlana Khlokhlova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Moscow Clinical Scientific Center</investigator_affiliation>
    <investigator_full_name>Zhukova Lyudmila</investigator_full_name>
    <investigator_title>Deputy Director of the Loginov Moscow Clinical Scientific Center, MD, PhD, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

